2022 Fiscal Year Research-status Report
Specificities of cellular uptake of primary cilium-derived extracellular vesicles for intercellular communication
| Project/Area Number |
21K15088
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
IJAZ FARYAL 広島大学, 医系科学研究科(医), 助教 (80845595)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | Primary Cilium / Ciliopathies |
|---|
| Outline of Annual Research Achievements |
Cell-intrinsic mechanisms of ciliopathies have been well studied. In contrast, cell-extrinsic factors that underlie ciliopathies have barely been explored.
We investigated the effects of extracellular bioactive factors derived from wildtype NIH/3T3 cells culture supernatant on the migration/ proliferation of primary cilium-deficient NIH/3T3-Kif3a-KO cells after wounding. The factors derived from wildtype NIH/3T3 cells culture supernatant increased the rate of cell migration/proliferation in target cells as compared to the factors derived from primary cilium-deficient cells culture supernatant from NIH/3T3-Kif3a-KO cells and NIH/3T3-Dync2h1-KO cells. Furthermore, by omics analysis of the supernatants, we found a molecule that showed a decline in the culture supernatant of primary cilium-deficient cells. These findings suggest that fibroblasts regulate cellular migration/proliferation process in primary cilium-deficient target cells via cell-extrinsic regulatory mechanisms in a primary cilium-dependent manner.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
The project is rather going smoothly because we identified some of the factors involved in cell-extrinsic regulation of ciliopathies.
|
| Strategy for Future Research Activity |
Task1. Evaluation of secretion profile: Confirmation of biofactors and signaling pathways.
Task2. Generate invitro models of ciliopathies using human cell lines.
|
| Causes of Carryover |
The amount was meant to be used for service fee for RNA sequencing, however, there was some problems with sample analysis from the service company.
In FY2023, the amount will be used to pay the service fee after sample optimization for RNA- sequencing analysis. Rest will be used as paper publication fee.
|
